Cholangiocarcinoma: The most common adverse reactions (incidence ≥ 20%) are hyperphosphatemia, alopecia, diarrhea, nail toxicity, fatigue, dysgeusia, nausea, constipation, stomatitis, dry eye, dry mouth, decreased appetite, vomiting, arthralgia, abdominal pain, hypophosphatemia, back pain, and dry skin.
Myeloid/lymphoid neoplasms with FGFR1 rearrangement: The most common (≥ 20%) adverse reactions are hyperphosphatemia, nail toxicity, alopecia, stomatitis, diarrhea, dry eye, fatigue, rash, abdominal pain, anemia, constipation, dry mouth, epistaxis, serous retinal detachment, extremity pain, decreased appetite, dry skin, dyspepsia, back pain, nausea, blurred vision, peripheral edema, and dizziness.
from FDA,2024.06
Important Safety Warnings for SelpercatinibUsing Selpercatinib may cause multipl···【more】
Release date:2026-04-20Recommended:88
If you experience side effects, your doctor may adjust your dose, temporarily st···【more】
Release date:2026-02-12Recommended:114
In the medical field, each drug comes with its specific therapeutic effects and ···【more】
Release date:2024-12-25Recommended:326
As an emerging drug, Selpercatinib has shown potential in the treatment of speci···【more】
Release date:2024-12-25Recommended:332
Selpercatinib blocks tumor growth and spread by inhibiting the kinase activity o···【more】
Release date:2024-08-16Recommended:314
Selpercatinib is an innovative RET inhibitor specifically designed to treat canc···【more】
Release date:2024-08-16Recommended:360
Selpercatinib is a highly selective RET inhibitor that inhibits the growth of tu···【more】
Release date:2024-08-16Recommended:298